The maturation of algorithmic discovery The pharmaceutical industry reached an inflection point in 2025 as artificial intelligence transitioned from a […]
How to fix the $2.6 billion drug discovery problem Read Post »
The pharmaceutical industry is struggling with its own productivity. The cost of bringing a single new chemical entity to market
The Asset Rescue Playbook: Turning Off-Patent Data into High-Margin Monopolies Read Post »
1. The Economics of Managed Exclusivity The pharmaceutical industry operates on a unique economic premise: huge upfront investment in research
Litigate, Settle, Repeat: The Strategic Architecture of Sequential Patent Suits Read Post »
Executive Summary The pharmaceutical sector currently faces a distinct legal friction where federal health policy conflicts with intellectual property statutes.
Executive Summary The biopharmaceutical and life sciences sectors face a central, defining strategic tension: the optimal allocation of capital between
The Capital Allocation Pain Point: Balancing R&D Burn with Defensible IP to Maximize ROI Read Post »
In the high-stakes world of pharmaceuticals and biotechnology, intellectual property (IP) is no longer a simple legal instrument; it is
Global Patent Thickets: The Cross-Border Pain Point Read Post »
The Valuator’s Teacup: Why Pharma Forecasting Is a High-Stakes Riddle The Fundamental Challenge of Pharmaceutical Valuation The pharmaceutical and biotechnology
Generic Entry Uncertainty: A Pain Point in Pharma Valuations Read Post »
The term “patent cliff” has served as a powerful and often terrifying metaphor in the pharmaceutical industry. It paints a
The Patent Cliff Panic: A Pain Point Every Pharma Investor Faces Read Post »
The High-Stakes Gamble: Why Late-Stage Drug Development Is a Ticking Time Bomb For investors, the biopharmaceutical pipeline represents both a
Pipeline Blind Spots: The Investor’s Hidden Pain Point Read Post »
Get fresh news and insights, drug patent expirations & more…
